Clincosm LogoSign in Get a demo

Diffuse Large B Cell Lymphoma

Showing NaN - NaN of 15
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab Vedotin, Rituximab)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Polatuzumab Vedotin, Rituximab
  • Shanghai, Shanghai, China
    Zhongshan Hospital，Fudan University
Jul 10, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab vedotin and Rituximab)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Polatuzumab vedotin and Rituximab
  • Shanghai, Shanghai, China
    Zhongshan Hospital，Fudan University
Jul 10, 2023

Extranodal Lymphoma or Lymphoma of Rare Pathological Types

Not yet recruiting
  • Lymphoma
  • +8 more
  • No interventions need to be specified for this study
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Jun 15, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • BTK inhibitor
  • PD-1 inhibitor
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma Trial in Australia, China (BGB-10188,

Recruiting
  • Chronic Lymphocytic Leukemia
  • +9 more
  • Adelaide, Australia
  • +12 more
Jan 6, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib plus R-ICE, Decitabine plus R-ICE, Chidamide plus R-ICE)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib plus R-ICE
  • +4 more
  • Shanghai, Shanghai, China
    Ruijin Hospital
Apr 26, 2022

Resistance to GNC-038 in Relapsed and Refractory Diffuse Large

Recruiting
  • Diffuse Large B Cell Lymphoma
    • Shanghai, Shanghai, China
      Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
    Apr 17, 2022

    Diffuse Large B Cell Lymphoma Trial in Shanghai (zanubrutinib)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Mar 13, 2022

    Diffuse Large B Cell Lymphoma Trial in Shanghai, Hangzhou (JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells))

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)
    • Shanghai, Shanghai, China
    • +1 more
    Mar 22, 2021

    Diffuse Large B Cell Lymphoma Trial in Shanghai (Ibrutinib, Lenalidomide, Rituximab)

    Unknown status
    • Diffuse Large B Cell Lymphoma
    • Shanghai, Shanghai, China
      Ruijin hospital
    Feb 15, 2021

    Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in China (CD19-targeted Chimeric Antigen

    Recruiting
    • Lymphoma, Non-Hodgkin
    • +2 more
    • CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
    • Beijing, Beijing, China
    • +9 more
    Jan 17, 2021

    Diffuse Large B Cell Lymphoma Trial in Shanghai (Cyclophosphamide, Rituximab, Doxorubicin)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • Shanghai, Shanghai, China
      Ruijin hospital
    Nov 17, 2020

    Diffuse Large B Cell Lymphoma Trial in Shanghai (Rituximab, Cyclophosphamide, Doxorubicin)

    Unknown status
    • Diffuse Large B Cell Lymphoma
    • Shanghai, China
      Shanghai Ruijin Hospital
    Mar 9, 2020

    Diffuse Large B Cell Lymphoma Trial in Shanghai (Lenalidomide 25mg)

    Unknown status
    • Diffuse Large B Cell Lymphoma
    • Lenalidomide 25mg
    • Shanghai, Shanghai, China
      Ruijin hospital
    Jul 4, 2019

    Diffuse Large B Cell Lymphoma Trial in China (Rituximab, Gemcitabine, Oxaliplatin)

    Unknown status
    • Diffuse Large B Cell Lymphoma
    • Wuhan, Hubei, China
    • +5 more
    Jan 1, 2019